Edwards Lifesciences Corp (EW) concluded trading on Thursday at a closing price of $69.86, with 5.71 million shares of worth about $399.16 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -19.99% during that period and on January 16, 2025 the price saw a loss of about -0.60%. Currently the company’s common shares owned by public are about 589.80M shares, out of which, 579.26M shares are available for trading.
Stock saw a price change of -5.79% in past 5 days and over the past one month there was a price change of -4.72%. Year-to-date (YTD), EW shares are showing a performance of -5.63% which decreased to -5.58% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $58.93 but also hit the highest price of $96.12 during that period. The average intraday trading volume for Edwards Lifesciences Corp shares is 4.96 million. The stock is currently trading -4.90% below its 20-day simple moving average (SMA20), while that difference is down -2.10% for SMA50 and it goes to -8.90% lower than SMA200.
Edwards Lifesciences Corp (NYSE: EW) currently have 589.80M outstanding shares and institutions hold larger chunk of about 84.85% of that.
The stock has a current market capitalization of $41.20B and its 3Y-monthly beta is at 1.11. PE ratio of stock for trailing 12 months is 10.08, while it has posted earnings per share of $6.93 in the same period. Its PEG reads 1.44 and has Quick Ratio of 2.89 while making debt-to-equity ratio of 0.07. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for EW, volatility over the week remained 2.46% while standing at 2.13% over the month.
Stock’s fiscal year EPS is expected to rise by 2.32% while it is estimated to decrease by -4.82% in next year. EPS is likely to shrink at an annualized rate of 7.00% for next 5-years, compared to annual growth of 15.35% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Wolfe Research on Jan-17-25 offering an Underperform rating for the stock and assigned a target price of $60 to it. On October 11, 2024, Morgan Stanley Resumed their recommendations, while on September 18, 2024, Jefferies Downgrade their ratings for the stock with a price target of $70. Stock get an Outperform rating from Daiwa Securities on July 31, 2024.
